RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 REPRISE 3b Study in Enrollment Phase
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 14
IS 49
SP 14
OP 14
DO 10.1177/155989771449009
UL http://mdc.sagepub.com/content/14/49/14.abstract
AB Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in adults and is the fourth-leading cause of end-stage renal disease. The Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [REPRISE 3b; NCT02160145] study's objective is to compare the efficacy of tolvaptan, a selective arginine vasopressin V2 receptor antagonist, with placebo in adults with ADPKD. Results are discussed in this article.